marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 12-05-2024
KalVista Pharmaceuticals Balance Sheet 2011-2024 | KALV
Annual Balance Sheet KalVista Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-44.7 M | -14.1 M | -32 M | -50.8 M | -31 M | -21.8 M | -49.1 M | 2.67 M | -6.72 M | -5.56 M | - |
Long Term Debt |
5.05 M | - | - | - | - | - | 3.15 M | 2.13 M | - | - | - |
Long Term Debt Current |
863 K | 588 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
5.05 M | 1.06 M | 3.34 M | 10.9 M | - | - | 3.21 M | 43.7 M | 39.9 M | 33.7 M | - |
Total Current Liabilities |
9.77 M | 7.72 M | 18.1 M | 23.2 M | 3.02 M | 3.25 M | 4.27 M | - | - | - | - |
Total Liabilities |
- | 8.78 M | 21.4 M | 34.1 M | 3.02 M | 3.25 M | 7.48 M | 50.8 M | 43.8 M | 36.8 M | - |
Deferred Revenue |
- | - | 9.54 M | 18.5 M | - | - | 29 K | 29 K | 29 K | 23 K | - |
Retained Earnings |
-168 M | -122 M | -92.5 M | -71.7 M | -55.9 M | -37.3 M | -72.6 M | -47.8 M | -34.4 M | -28.7 M | - |
Total Assets |
272 M | 92.5 M | 118 M | 61.4 M | 34.3 M | 24.7 M | 56.8 M | 6.64 M | 10.1 M | 8.53 M | - |
Cash and Cash Equivalents |
50.6 M | 15.8 M | 32 M | 51.1 M | 31 M | 21.8 M | 53.7 M | 3.9 M | - | - | - |
Book Value |
272 M | 83.8 M | 96.7 M | 27.3 M | 31.3 M | 21.5 M | 49.3 M | -44.2 M | -33.7 M | -28.3 M | - |
Total Shareholders Equity |
257 M | 83.8 M | 96.7 M | 27.3 M | 31.3 M | -37.1 M | 49.3 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet KalVista Pharmaceuticals
| 2024-Q3 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
4.68 M | 6.02 M | 6.26 M | 6.55 M | 6.86 M | 7.14 M | 7.47 M | 7.7 M | 8.01 M | 7.21 M | 1.12 M | 6.22 M | 6.47 M | 5.05 M | 926 K | 932 K | 1.01 M | 1.06 M | - | 1.05 M | 1.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
4.68 M | 6.02 M | 6.26 M | 6.55 M | 6.86 M | 7.14 M | 7.47 M | 7.7 M | 8.01 M | 7.21 M | 1.12 M | 6.22 M | 6.47 M | 5.05 M | 3.43 M | 932 K | 1.01 M | 1.06 M | 3.67 M | 3.81 M | 4.05 M | 3.34 M | 14 M | 4.67 M | 8.46 M | 10.9 M | - | 149 K | 213 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.93 M | 1.97 M | 6.6 M | 7.48 M | 7.46 M | 7.48 M | 7.48 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34 M | - | - | - | 12.3 M | 2.6 M | 6.02 M | 9.54 M | 20 M | 14.8 M | 17.2 M | 18.5 M | - | - | - | - | - | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | 29 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-552 M | -470 M | -425 M | -396 M | -368 M | -343 M | -226 M | -295 M | -273 M | -250 M | -153 M | -204 M | -184 M | -168 M | -115 M | -143 M | -132 M | -122 M | -84 M | -115 M | -106 M | -92.5 M | -71 M | -80 M | -76.7 M | -71.7 M | -51.7 M | -65.8 M | -60.8 M | -55.9 M | - | -89 M | -86.6 M | -79.2 M | -72.6 M | -67 M | -72.6 M | -72.6 M | -47.8 M | -47.8 M | -47.8 M | -47.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
161 M | 235 M | 114 M | 139 M | 160 M | 183 M | 225 M | 163 M | 182 M | 204 M | 66.2 M | 244 M | 259 M | 272 M | 103 M | 75.4 M | 83.9 M | 92.5 M | 127 M | 112 M | 120 M | 118 M | 66.7 M | 133 M | 57.6 M | 61.4 M | 38 M | 34.7 M | 30.8 M | 34.3 M | - | 35.9 M | 38 M | 49.7 M | 56.8 M | 62.1 M | 56.8 M | 56.8 M | 6.64 M | 6.64 M | 6.64 M | 6.64 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
41.6 M | 31.8 M | 23.1 M | 57.7 M | 49.4 M | 56.2 M | 45.6 M | 38.6 M | 37.9 M | 30.7 M | 17.7 M | 46.5 M | 48.3 M | 50.6 M | 18.6 M | 16.2 M | 18 M | 15.8 M | 56.3 M | 21.7 M | 30.1 M | 32 M | 58.7 M | 121 M | 48.1 M | 48.1 M | 33.5 M | 28.1 M | 28.1 M | 26.5 M | - | 35.2 M | 36.8 M | 48.5 M | 53.7 M | 59.9 M | 53.7 M | 53.7 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 9.78 M | - | - | - | 8.24 M | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | - | - | 225 M | 163 M | 182 M | 204 M | 66.2 M | 244 M | 259 M | 272 M | 103 M | 75.4 M | 83.9 M | 92.5 M | 127 M | 112 M | 120 M | 118 M | 66.7 M | 133 M | 57.6 M | 61.4 M | 38 M | 34.7 M | 30.8 M | 34.3 M | - | 33.9 M | 36 M | 43.1 M | 49.3 M | 54.6 M | 49.3 M | 49.3 M | -4.62 M | -4.62 M | -4.62 M | -4.62 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
134 M | 207 M | 88.6 M | 114 M | 139 M | 161 M | 184 M | 144 M | 165 M | 185 M | 58.6 M | 227 M | 244 M | 244 M | 89.7 M | 65 M | 65 M | 74.4 M | 104 M | 97.8 M | 97.8 M | 102 M | 28.6 M | 107 M | 107 M | 26.2 M | 34.8 M | 31.1 M | 31.1 M | 26.7 M | - | 33.9 M | 36 M | 43.1 M | 49.3 M | 54.6 M | 49.3 M | 49.3 M | -44.2 M | -44.2 M | -44.2 M | -44.2 M | -33.7 M | - | - | - | -28.3 M | - | - | - | - | - | - | - |
All numbers in USD currency